Neogenomics (NEO) Cash from Financing Activities (2010 - 2026)

Neogenomics (NEO) has 17 years of Cash from Financing Activities data on file, last reported at -$12.2 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 93.95% year-over-year to -$12.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$11.4 million (up 94.3% YoY) and the FY2025 annual result came in at -$200.3 million, down 4410.98% from the prior year.
• Cash from Financing Activities slipped to -$12.2 million in Q2 2026, from -$338000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $6.1 million in Q1 2022 to a low of -$202.4 million in Q2 2025.
• A 5-year average of -$10.7 million and a median of $980000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 2971.88% — and 2025, when it sank 10396.69%.
• Tracing NEO's Cash from Financing Activities over 5 years: stood at $1.8 million in 2022, then declined by 29.52% to $1.3 million in 2023, then plunged by 45.91% to $687000.0 in 2024, then plunged by 37.26% to $431000.0 in 2025, then plunged by 2940.84% to -$12.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$12.2 million (Q2 2026), -$338000.0 (Q1 2026), and $431000.0 (Q4 2025), per Business Quant data.